title: [Complement fragments in patients with bronchial asthma].
abstract: In this study, we investigated the pharmacological reactions induced by ibudilast to the complement system with the aim of clarifying the functional relation of the complement system to allergic reactions and pathology in patients with bronchial asthma. Complement hemolytic activities (CH50 and ACH50), complement profile, anaphylatoxins (C3a and C5a) and complement fragments (Bb, iC3b and C4d) were measured in 20 patients with bronchial asthma. One of antiasthmatic activities induced by ibudilast was concluded to be brought about though inactivation of the alternative complement pathway working on type III allergic reaction. Ibudilast increased the complement fragment Bb in the patients' plasma with the fairly controlled bronchial asthma. This increase in circulating Bb was suspected to be a result of inactivation of intermediate complement complexes, for example C3b.Bb.P, because the amounts in plasma of C3 and C5 showed no changes, while those of factor, B, P, H and I were decreased by ibudilast administration in patients with fairly controlled bronchial asthma. This antiasthmatic ability of ibudilast was restrained in those patients whose peripheral leukocytopenia was advanced before ibudilast administration, and in those whom ibudilast did not provoke an increase in the plasma level of iC3b, or did not prevent the serum level of C5 from increasing. In those unfairly controlled cases, enough anaphylatoxins, especially C5a might be produced to make the margination of peripheral neutrophils to the lung and increase CR3 on neutrophils binding with iC3b.
authors.affiliation: Division of Pulmonary Disease, Yosanoumi Kyoto Prefectural Hospital.
authors.forename: H
authors.initials: H
authors.lastname: Onodera
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: S
authors.initials: S
authors.lastname: Takemura
authors.forename: T
authors.initials: T
authors.lastname: Doi
authors.forename: Y
authors.initials: Y
authors.lastname: Kasamatsu
authors.forename: K
authors.initials: K
authors.lastname: Yanagida
authors.forename: W
authors.initials: W
authors.lastname: Fukuda
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: M
authors.initials: M
authors.lastname: Deguchi
authors.forename: M
authors.initials: M
authors.lastname: Ueda
mesh_terms: D000328:Adult; D000368:Aged; D000706:Anaphylatoxins / Q000032:analysis; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D001980:Bronchi / Q000276:immunology; D015941:Complement Hemolytic Activity Assay; D003165:Complement System Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D010446:Peptide Fragments / Q000032:analysis; D011725:Pyridines / Q000627:therapeutic use; D011951:Receptors, Complement / Q000378:metabolism; D007212:Indolizines; D011720:Pyrazoles
chemical_list: D000706:Anaphylatoxins; D003165:Complement System Proteins; D010446:Peptide Fragments; D011725:Pyridines; D011951:Receptors, Complement; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles